Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization ...
Seeking Alpha

Belay Diagnostics Announces US Commercial Launch of Summit™: Breakthrough CSF Testing for CNS Cancer Detection and Management

Validation Data on More Than 100 Patients published in Journal of Molecular Diagnostics CHICAGO, April 25, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the ...

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, ...
Yahoo

Groundbreaking new brain cancer test has an 80% accuracy rate with no false positives

Add Yahoo as a preferred source to see more of our stories on Google. A new brain cancer test using spinal fluid detects tumors with 100% accuracy, offering safer diagnosis and fewer risky biopsies.
ascopubs.org

Is cerebrospinal fluid cytology a useful test?

IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging, and immunohistochemical study in 34 patients with glioma. Background: Cerebrospinal ...

Plus Therapeutics Inc.: Plus Therapeutics Receives AMA PLA Code for CNSide CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ...